Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the Canadian launch of Beteflam™ (betamethasone valerate), a novel, patent-protected patch,...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ralph Bohrer has joined the Company in the position of President and General Manager of its U.S....

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming...

Q4 revenue up 30%, Company significantly advances strategic plans to build a dermatology growth company MISSISSAUGA, ON, Feb. 24, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the Canadian launch of Actikerall™ (0.5% fluorouracil and 10% salicylic acid), indicated for the...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Sitavig™ has been accepted for review by Health Canada. Sitavig...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it will host a conference call for its Q4 and full-year 2015 financial results on Wednesday, February...

– Will Represent Fourth Commercial Product in Cipher's Growing Canadian Dermatology Business – MISSISSAUGA, ON, Dec. 7, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, and Norman Evans, Chief Financial...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will be presenting at the TD...

– Quarter Highlighted by 28% Revenue Growth, $2.3 Million in Cash Flow from Operations and Strong Advancement of Pre-Commercial Portfolio – MISSISSAUGA, ON, Nov. 4, 2015 /CNW/ - Cipher...

Cipher Pharmaceutiquired to build its commercial infrastructure in Canada. ____________________ 1 Source: IMS Health. Market share calculated based on total isotretinoin prescriptions. Product...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Company, along with its partners, Ranbaxy Pharmaceuticals, Inc. ("Ranbaxy"), a Sun Pharma...

– Quarter Highlighted by Continued Solid Performance from Isotretinoin Products and Acquisition and Integration of Innocutis – MISSISSAUGA, ON, Aug. 14, 2015 /CNW/ - Cipher Pharmaceuticals...

- Acceptance marks first regulatory filing with FDA since Absorica® in 2011 - MISSISSAUGA, ON, Aug. 4, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2015 financial results on Friday, August 14, 2015. Q2 2015 CONFERENCE CALL WHEN:...

- Company expects to submit Ozenoxacin for regulatory approval in Canada in the first quarter of 2016 - MISSISSAUGA, ON, July 30, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 2015 JMP Securities Life Sciences...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the BIO International Convention in...

- Company Adds Regulatory and Alliance Management Expertise to Support Expanded Product Portfolio - MISSISSAUGA, ON, June 2, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH)...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special...

– Company Achieves Significant Progress Across All Three Components of Growth Strategy – MISSISSAUGA, ON, May 13, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa®...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q1 2015 financial results and hold its Annual and Special Meeting of Shareholders on...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Court has issued an opinion in the claim construction hearing (commonly referred to as a...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor...

Accelerates development of a leading North American dermatology company Adds U.S. commercial infrastructure for our acquisition/in-licensing activities Raises US$100 million Senior Notes to...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will participate at the Laurentian Bank Securities 2nd Annual...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Cowen and Company 35th Annual Health Care...

– Strengthens dermatology product pipeline with rights to three products – MISSISSAUGA, ON, Feb. 26, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and 12 months ended December 31, 2014. Financial...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Beteflam Patch (previously called the Betesil® Patch) has been accepted for review by...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q4 and year-end 2014 financial results on Wednesday, February 25, 2015. Q4 AND YEAR-END...

Company also announces promotions of Peter Weiler and Linda Angaritis MISSISSAUGA, ON, Jan. 19, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has acquired the assets of Melanovus Oncology Inc. ("Melanovus"), a Hershey (Pennsylvania)-based...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that it has licensed the Canadian rights to Ozenoxacin, a topical treatment for adult and paediatric...

Cipher Pharmaceuticals Inc. (the "Company") (TSX: CPH; NASDAQ: CPHR) ("Cipher" or "the Company") announced today that its Board of Directors has approved a By-Law (the "Advance Notice By-Law")...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare...

Cipher Pharmaceuticals Inc. ("Cipher" or the "Company") (TSX:DND, NASDAQ:CPHR) today announced that its common shares have been approved for listing and trading on the NASDAQ Global Market (the...

- Company also announces application to list on NASDAQ - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 29, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its...

Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), today announced it will host a conference call for its Q3 2014 financial results on Wednesday, October 29, 2014. Q3 2014 CONFERENCE CALL WHEN:...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced Shawn Patrick O'Brien, President and Chief Executive Officer, is presenting at the Rodman & Renshaw 16th Annual...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2014. Q2 2014 Highlights Total revenue of $8.7 million, an...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has entered into a definitive distribution and supply agreement with Ranbaxy Laboratories Ltd. ("Ranbaxy") under which Cipher has granted...

Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), today announced it will host a conference call for its Q2 2014 financial results on Wednesday, July 30, 2014. Q2 2014 CONFERENCE CALL WHEN:...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien has been appointed Chief Executive Officer of Cipher, effective June 30. Mr. O'Brien...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has entered into a definitive distribution and supply agreement with Laboratorios Andrómaco S.A. ("Andrómaco") under which Cipher has...